BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe • Euronext Paris • EPA:BLC • FR0000035370
22.45 EUR
+0.35 (+1.58%)
Last: Feb 4, 2026, 07:00 PM
Taking everything into account, BLC scores 4 out of 10 in our fundamental rating. BLC was compared to 33 industry peers in the Health Care Providers & Services industry. BLC has an average financial health and profitability rating. BLC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- BLC had positive earnings in the past year.
- In the past year BLC had a positive cash flow from operations.
- BLC had positive earnings in 4 of the past 5 years.
- BLC had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of BLC (0.08%) is worse than 72.73% of its industry peers.
- BLC has a Return On Equity of 0.74%. This is in the lower half of the industry: BLC underperforms 66.67% of its industry peers.
- BLC has a Return On Invested Capital of 6.43%. This is in the better half of the industry: BLC outperforms 75.76% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BLC is in line with the industry average of 5.90%.
- The last Return On Invested Capital (6.43%) for BLC is above the 3 year average (6.14%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROIC | 6.43% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
1.3 Margins
- BLC has a worse Profit Margin (0.11%) than 72.73% of its industry peers.
- In the last couple of years the Profit Margin of BLC has declined.
- BLC has a better Operating Margin (8.21%) than 66.67% of its industry peers.
- BLC's Operating Margin has been stable in the last couple of years.
- BLC's Gross Margin of 67.80% is fine compared to the rest of the industry. BLC outperforms 75.76% of its industry peers.
- In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.21% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% |
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
- BLC has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for BLC remains at a similar level compared to 5 years ago.
- Compared to 1 year ago, BLC has an improved debt to assets ratio.
2.2 Solvency
- BLC has an Altman-Z score of 1.37. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
- BLC has a Altman-Z score of 1.37. This is comparable to the rest of the industry: BLC outperforms 42.42% of its industry peers.
- BLC has a debt to FCF ratio of 12.90. This is a negative value and a sign of low solvency as BLC would need 12.90 years to pay back of all of its debts.
- The Debt to FCF ratio of BLC (12.90) is comparable to the rest of the industry.
- A Debt/Equity ratio of 5.29 is on the high side and indicates that BLC has dependencies on debt financing.
- Looking at the Debt to Equity ratio, with a value of 5.29, BLC is doing worse than 84.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Altman-Z | 1.37 |
ROIC/WACC1.25
WACC5.16%
2.3 Liquidity
- A Current Ratio of 1.38 indicates that BLC should not have too much problems paying its short term obligations.
- BLC has a Current ratio of 1.38. This is in the better half of the industry: BLC outperforms 69.70% of its industry peers.
- A Quick Ratio of 1.18 indicates that BLC should not have too much problems paying its short term obligations.
- The Quick ratio of BLC (1.18) is better than 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 158.33% over the past year.
- Measured over the past years, BLC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.37% on average per year.
- Looking at the last year, BLC shows a small growth in Revenue. The Revenue has grown by 6.35% in the last year.
- Measured over the past years, BLC shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
3.2 Future
- Based on estimates for the next years, BLC will show a small growth in Earnings Per Share. The EPS will grow by 6.75% on average per year.
- Based on estimates for the next years, BLC will show a small growth in Revenue. The Revenue will grow by 7.69% on average per year.
EPS Next Y-4.33%
EPS Next 2Y0.96%
EPS Next 3Y6.75%
EPS Next 5YN/A
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- BLC is valuated quite expensively with a Price/Earnings ratio of 320.71.
- Compared to the rest of the industry, the Price/Earnings ratio of BLC indicates a slightly more expensive valuation: BLC is more expensive than 72.73% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.25. BLC is valued rather expensively when compared to this.
- The Price/Forward Earnings ratio is 11.17, which indicates a very decent valuation of BLC.
- 78.79% of the companies in the same industry are more expensive than BLC, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of BLC to the average of the S&P500 Index (27.50), we can say BLC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 320.71 | ||
| Fwd PE | 11.17 |
4.2 Price Multiples
- 87.88% of the companies in the same industry are more expensive than BLC, based on the Enterprise Value to EBITDA ratio.
- 81.82% of the companies in the same industry are more expensive than BLC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.19 | ||
| EV/EBITDA | 5.43 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.96%
EPS Next 3Y6.75%
5. Dividend
5.1 Amount
- No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:BLC (2/4/2026, 7:00:00 PM)
22.45
+0.35 (+1.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13 2025-11-13
Earnings (Next)02-12 2026-02-12
Inst Owners11.61%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap165.46M
Revenue(TTM)491.18M
Net Income(TTM)533.00K
Analysts83.33
Price Target36.21 (61.29%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP106.75%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.39%
PT rev (3m)-1.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-19.6%
EPS NY rev (3m)-22.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 320.71 | ||
| Fwd PE | 11.17 | ||
| P/S | 0.34 | ||
| P/FCF | 5.19 | ||
| P/OCF | 1.8 | ||
| P/B | 2.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.43 |
EPS(TTM)0.07
EY0.31%
EPS(NY)2.01
Fwd EY8.95%
FCF(TTM)4.32
FCFY19.26%
OCF(TTM)12.48
OCFY55.58%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.93
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.08% | ||
| ROE | 0.74% | ||
| ROCE | 8.75% | ||
| ROIC | 6.43% | ||
| ROICexc | 6.81% | ||
| ROICexgc | 12.17% | ||
| OM | 8.21% | ||
| PM (TTM) | 0.11% | ||
| GM | 67.8% | ||
| FCFM | 6.49% |
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.29 | ||
| Debt/FCF | 12.9 | ||
| Debt/EBITDA | 3.78 | ||
| Cap/Depr | 99.07% | ||
| Cap/Sales | 12.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.09% | ||
| Profit Quality | 5980.3% | ||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.18 | ||
| Altman-Z | 1.37 |
F-Score8
WACC5.16%
ROIC/WACC1.25
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y-4.33%
EPS Next 2Y0.96%
EPS Next 3Y6.75%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year3.87%
Revenue Next 2Y4.87%
Revenue Next 3Y5.16%
Revenue Next 5Y7.69%
EBIT growth 1Y18.78%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year137.78%
EBIT Next 3Y39.06%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%
BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ
Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.
Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?
ChartMill assigns a valuation rating of 4 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.
Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?
BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.
What is the expected EPS growth for BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?
The Earnings per Share (EPS) of BASTIDE LE CONFORT MEDICAL (BLC.PA) is expected to decline by -4.33% in the next year.
Can you provide the dividend sustainability for BLC stock?
The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 106.75%.